Generation of Clinically Applicable CAR-NKT Cells Research Background Chimeric Antigen Receptor (CAR) T cell therapy has been approved by the Food and Drug Administration (FDA) for the treatment of B-cell malignancies and multiple myeloma. However, the use of autologous CAR-T cell products presents challenges such as high costs, long manufacturing ...
AAV-SB-CRISPR Screening Identifies Genetic Checkpoints in Tumor-Infiltrating Primary Natural Killer Cells for CAR-NK Therapy With the rapid advancement of biotechnology and gene editing technologies, increasing attention is being paid to enhancing the clinical potential of natural killer (NK) cells in cancer therapy. Despite their potential in clin...
Application of Base Editing Screening Technology in Tumor Immunotherapy T Cell Research Immune cell therapies, such as T cell transfer therapy and CAR T cell therapy, have become important clinical cancer treatment tools in certain disease fields. However, most cancer patients fail to benefit from cell therapies, possibly due to inherent changes in...
Engineering Selective Gene Drives to Steer Tumor Evolution to Counteract Drug Resistance As tumors evolve, targeted therapies against cancer often fail due to the evolution of drug resistance. This study demonstrates a way to manipulate tumor evolution repeatedly to design therapeutic opportunities, even in the presence of genetic heterogeneity. We...
Long-term Model for Studying Tumor Microenvironment Complexity: Patient-derived Mini-colons Background: The interaction between tumors and their surrounding microenvironment has profound implications for cancer development and treatment. However, existing in vitro tumor models lack the ability to capture these complex interactions. To address this ...
Single-Sample Tumor Subclonal Reconstruction Algorithm Based on Crowd-Sourced Resources Background The evolution of cancer and the genetic heterogeneity of tumors are critical fields in modern oncology research. Tumors evolve from normal cells through progressive acquisition of somatic mutations. These mutations occur probabilistically, influenced ...
Nucleotide Base Adducts Bind MR1 and Stimulate MR1-Restricted T Cells Abstract This article provides an overview of the latest research by Vacchini et al. on MR1-restricted T cells (MR1T cells), which discovered the presence of nucleotide base adducts as MR1T cell antigens and unveiled their metabolic pathways and physiological functions in tumor c...
TREM2 Deficiency Remodels Intestinal Macrophages and Microbiota to Enhance Anti-PD-1 Tumor Immunotherapy A research team from the Washington University School of Medicine, led by Blanda Di Luccia and other scientists, recently published a study in the journal Science Immunology, revealing how intestinal microbiota and tumor-associated macrophages i...
Immunoglobulin Superfamily Ligand B7H6 Enables T Cell Responses under NK Cell Surveillance Background In the field of immunology, understanding the mechanisms regulating T cell immunity is crucial for developing effective therapies for diseases related to T cell dysfunction, such as autoimmune diseases, chronic infections, and cancer. T cells media...
Immunotherapy Checkpoint Inhibitors (ICIs, also known as immune checkpoint blockers) are a class of drugs that have achieved significant breakthroughs in cancer immunotherapy in recent years. These drugs mainly work by blocking Programmed Death Protein 1 (PD-1) and Cytotoxic T-lymphocyte-associated Protein 4 (CTLA-4), thereby activating anti-tumor ...